Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Covington
Chinese Patent Office
Accenture
Deloitte
Cerilliant
Julphar
Cantor Fitzgerald

Generated: May 25, 2018

DrugPatentWatch Database Preview

Desvenlafaxine succinate - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for desvenlafaxine succinate and what is the scope of desvenlafaxine succinate freedom to operate?

Desvenlafaxine succinate
is the generic ingredient in two branded drugs marketed by Actavis Labs Fl, Alembic Pharms Ltd, Casi Pharms Inc, Lupin Ltd, Mylan Pharms Inc, West-ward Pharms Int, Zydus Pharms Usa Inc, and Wyeth Pharms Inc, and is included in nine NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Desvenlafaxine succinate has sixty-eight patent family members in thirty-two countries.

There are sixteen drug master file entries for desvenlafaxine succinate. Eighteen suppliers are listed for this compound.
Medical Subject Heading (MeSH) Categories for desvenlafaxine succinate

US Patents and Regulatory Information for desvenlafaxine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
West-ward Pharms Int DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204082-001 Feb 16, 2016 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Alembic Pharms Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204003-002 Jun 29, 2015 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Zydus Pharms Usa Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204020-001 Oct 11, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for desvenlafaxine succinate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508 Succinate salt of O-desmethyl-venlafaxine ➤ Try a Free Trial
7,291,347 Succinate salt of O-desmethyl-venlafaxine ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Baxter
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Daiichi Sankyo
Farmers Insurance
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.